<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">TCM</journal-id><journal-title-group><journal-title>Traditional Chinese Medicine</journal-title></journal-title-group><issn pub-type="epub">2166-6067</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/TCM.2021.104069</article-id><article-id pub-id-type="publisher-id">TCM-43756</article-id><article-categories><subj-group subj-group-type="heading"><subject>TCM20210400000_53613540.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  曲妥珠单抗所致乳腺癌患者心脏毒性的中西医结合治疗进展
  Research Progress of the Treatment of Combined Traditional Chinese and Western Medicine on Cardiotoxicity of Breast Cancer Patients Caused by Trastuzumab
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>项</surname><given-names>莲莲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>炜</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>上海市普陀区真如镇街道社区卫生服务中心，上海</addr-line></aff><aff id="aff3"><addr-line>上海中医药大学附属龙华医院，上海</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>06</month><year>2021</year></pub-date><volume>10</volume><issue>04</issue><fpage>511</fpage><lpage>515</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  曲妥珠单抗是针对人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER-2)基因突变型乳腺癌靶向治疗的首选药物。心脏毒性是其最主要的不良反应之一。西医治疗手段主要以对症治疗为主，临床使用存在一定的局限性。中医药对治疗靶向药物心脏毒性具有一定的优势。本文对曲妥珠单抗所致乳腺癌患者心脏毒性的中西医结合治疗进行综述。
  Trastuzumab is the drug of choice for targeted therapy of human epidermal growth factor receptor 2 (HER-2) gene mutant breast cancer. Cardiotoxicity is one of its main adverse effects. Western medicine treatment methods are mainly symptomatic treatment, and there are certain limitations in clinical use. Traditional Chinese medicine has certain advantages in treating cardiotoxicity of targeted therapy. This article reviews the treatment of combined traditional Chinese and Western medicine on the cardiotoxicity of breast cancer patients caused by trastuzumab.
 
</p></abstract><kwd-group><kwd>曲妥珠单抗，心脏毒性，HER2阳性乳腺癌，中医药, Trastuzumab</kwd><kwd> Cardiotoxicity</kwd><kwd> HER2-Positive Breast Cancer</kwd><kwd> Traditional Chinese Medicine</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>曲妥珠单抗是针对人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER-2)基因突变型乳腺癌靶向治疗的首选药物。心脏毒性是其最主要的不良反应之一。西医治疗手段主要以对症治疗为主，临床使用存在一定的局限性。中医药对治疗靶向药物心脏毒性具有一定的优势。本文对曲妥珠单抗所致乳腺癌患者心脏毒性的中西医结合治疗进行综述。</p></sec><sec id="s2"><title>关键词</title><p>曲妥珠单抗，心脏毒性，HER2阳性乳腺癌，中医药</p></sec><sec id="s3"><title>Research Progress of the Treatment of Combined Traditional Chinese and Western Medicine on Cardiotoxicity of Breast Cancer Patients Caused by Trastuzumab<sup> </sup></title><p>Lianlian Xiang<sup>1</sup>, Wei Hao<sup>2*</sup></p><p><sup>1</sup>Zhenru Town Community Health Service Center of Putuo District of Shanghai, Shanghai</p><p><sup>2</sup>Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai</p><p><img src="//html.hanspub.org/file/6-2270706x4_hanspub.png" /></p><p>Received: May 17<sup>th</sup>, 2021; accepted: Jun. 29<sup>th</sup>, 2021; published: Jul. 8<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/6-2270706x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Trastuzumab is the drug of choice for targeted therapy of human epidermal growth factor receptor 2 (HER-2) gene mutant breast cancer. Cardiotoxicity is one of its main adverse effects. Western medicine treatment methods are mainly symptomatic treatment, and there are certain limitations in clinical use. Traditional Chinese medicine has certain advantages in treating cardiotoxicity of targeted therapy. This article reviews the treatment of combined traditional Chinese and Western medicine on the cardiotoxicity of breast cancer patients caused by trastuzumab.</p><p>Keywords:Trastuzumab, Cardiotoxicity, HER2-Positive Breast Cancer, Traditional Chinese Medicine</p><disp-formula id="hanspub.43756-formula24"><graphic xlink:href="//html.hanspub.org/file/6-2270706x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-2270706x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-2270706x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>根据世界卫生组织国际癌症研究机构(IARC) 2020年发布全球最新癌症数据显示，乳腺癌已经超过肺癌成为全球最常见的恶性肿瘤 [<xref ref-type="bibr" rid="hanspub.43756-ref1">1</xref>]，全世界每年约新增120万乳腺癌患者，每年新老患者中约50万人死于乳腺癌。随着分子靶向治疗、免疫治疗等新型治疗手段的发展，乳腺癌患者的生存得到了极大的提高 [<xref ref-type="bibr" rid="hanspub.43756-ref2">2</xref>]。对于乳腺癌的治疗除了传统的手术、放化射治疗和内分泌治疗等治疗手段外。随着分子生物学技术的发展，针对人类表皮生长因子受体2 (human epidermal growth factor receptor 2, HER-2)基因的靶向治疗由于其疗效明确，毒副作用相对较小，已成为HER-2阳性乳腺癌的标准治疗方案。然而，一系列临床研究发现，心脏毒性是曲妥珠单抗治疗过程中最主要的不良反应之一 [<xref ref-type="bibr" rid="hanspub.43756-ref3">3</xref>]。部分患者因而不能完成全程治疗而达不到最佳疗效，增加了肿瘤复发转移的机率。因此，在曲妥珠单抗治疗的同时，检测其心脏毒性，制定安全有效的心脏保护策略至关重要。近年来，中医药防治抗肿瘤治疗不良反应疗效确切，安全性佳。本文将曲妥珠单抗所致心脏毒性的临床表现、机制、诊断及中西医防治策略做如下综述。</p></sec><sec id="s6"><title>2. 临床表现</title><p>根据目前的临床试验及临床实践，曲妥珠单抗所致心脏毒性主要表现为无临床症状的左心室射血分数(Left Ventricular Ejection Fractions, LVEF)下降，其发生率在4.2%~13.1%之间，其差异或与各临床试验中判定LVEF降低的标准不同有关。综合各大临床试验，目前LVEF降低的标准为LVEF低于55%或较治疗前降低10%以上 [<xref ref-type="bibr" rid="hanspub.43756-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43756-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.43756-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.43756-ref7">7</xref>]。同时，有一项荟萃分析报道，在11882名早期或晚期乳腺癌患者使用曲妥珠单抗的过程中，有7.5% (891/11882)的患者发生了无临床症状的LVEF下降；1.9% (226/11882)的患者发生了充血性心力衰竭(congestive heart failure, CHF)，而1% (119/11882)的患者甚至发生了心源性死亡 [<xref ref-type="bibr" rid="hanspub.43756-ref8">8</xref>]。</p></sec><sec id="s7"><title>3. 曲妥珠单抗所致心脏毒性机制</title><p>曲妥珠单抗所致心脏毒性的机制尚存在争议。根据抗肿瘤药物所致心脏毒性分类来看，曲妥珠单抗通常情况下不会引起心肌细胞形态改变，心肌活检显示与超微结构改变无关，属于II型心脏毒性 [<xref ref-type="bibr" rid="hanspub.43756-ref9">9</xref>]。HER2基因作为原癌基因，可激活包括MAPK/ERK通路、PI3K-AKT-mTOR等多个信号通路，从而抑制肿瘤细胞凋亡，肿瘤细胞过度增殖，并进一步增加了其侵袭性 [<xref ref-type="bibr" rid="hanspub.43756-ref10">10</xref>]。同时，HER2基因在正常细胞的生长增殖中起到关键性作用。心肌细胞同样富含HER2基因，HER2基因在维持心肌细胞正常生理活动中发挥了重要作用。曲妥珠单抗可靶向性的作用于HER2基因表达细胞，在HER2过表达的肿瘤细胞，通过阻断其信号通路从而抑制肿瘤细胞增殖，发挥抗肿瘤作用。在心肌细胞，曲妥珠单抗通过与HER2基因特异性结合，阻断其维持心肌细胞正常运作的信号通路，导致心脏功能失调。有研究发现，小鼠在敲除了HER2基因后可发生明显的LVEF降低 [<xref ref-type="bibr" rid="hanspub.43756-ref11">11</xref>]。此外，其毒性机制还可能与神经调节蛋白1，ErbB信号通路改变及心肌氧化应激，激活细胞凋亡有关 [<xref ref-type="bibr" rid="hanspub.43756-ref12">12</xref>]。</p></sec><sec id="s8"><title>4. 曲妥珠单抗心脏毒性诊断标准</title><p>曲妥珠单抗心脏毒性诊断标准可参考心脏毒性审查和评估委员会(cardiac toxicity review and evaluation committee, CREC)的诊断标准或可应用NCI CTCAE 4.0作为评价标准 [<xref ref-type="bibr" rid="hanspub.43756-ref13">13</xref>]。由于LVEF检测手段较简便，评价标准较客观。故临床上可以LVEF作为评价曲妥珠单抗心脏毒性的简易标准：伴随有症状时，LVEF较基线期下降至少5%，且&lt;55%；不伴随症状时，LVEF较基线期下降至少10%，且&lt;55%。</p></sec><sec id="s9"><title>5. 曲妥珠单抗心脏毒性的防治</title><sec id="s9_1"><title>5.1. 曲妥珠单抗心脏毒性的检测与评估</title><p>根据欧洲指南，通常在基线、第3、6、9个月(治疗期)和第12、18个月(治疗后)对患者进行心功能检测 [<xref ref-type="bibr" rid="hanspub.43756-ref14">14</xref>]。由于LVEF是判断心肌收缩能力的指标之一，而心肌收缩能力在一定程度上反应了心脏的功能，故LVEF降低常常表明患者心功能不全。所以对于LVEF的检测显得尤为重要。目前国内主要采用超声心动图(echocardiogram)作为主要检测手段 [<xref ref-type="bibr" rid="hanspub.43756-ref15">15</xref>]。超声心动图具有简便易行，无创性的优势，但LVEF对早期心脏毒性并不敏感。近年来，一些新型技术如多普勒成像，斑点追踪显像技术和实时三维超声心动图等技术得到了推广，已有临床试验探讨其在检测曲妥珠单抗心脏毒性中的应用。除了影像技术外，生物标志物如心肌肌钙蛋白(cTnI)可监测到早期的心肌损伤，弥补了LVEF的不足，同时其特异性也较高。B型钠尿肽(BNP)在血液中的浓度通常与心衰程度成正相关，故临床通常用来评价心功能，有排除心衰的阴性预测价值(&lt;100 pg/ml) [<xref ref-type="bibr" rid="hanspub.43756-ref16">16</xref>]。</p></sec><sec id="s9_2"><title>5.2. 曲妥珠单抗心脏毒性的西医治疗</title><p>欧洲心脏病协会(ESC)指南推荐在无症状LVEF下降时应用ACEI类或ARB类药物、β受体阻滞剂、他汀类药物。如果LVEF &lt; 40%时，必须使用AECI或ARB类药物，如果有症状的心衰患者伴体液潴留可加用利尿剂。然而，上述药物其结论主要基于临床观察性试验，证据结论较低。有研究比较了使用ACEI或ARB类药物、β受体阻滞剂在早期乳腺癌患者中预防曲妥珠单抗心脏毒性的作用，然后，上述药物均未能防治患者LVEF的降低。所以，就目前来说，西医防治曲妥珠单抗所致心脏毒性的策略疗效较低，缺乏有效的防治手段。</p></sec><sec id="s9_3"><title>5.3. 曲妥珠单抗心脏毒性的中医治疗</title><sec id="s9_3_1"><title>5.3.1. 病因病机</title><p>古代文献中没有明确记载曲妥珠单抗心脏毒性，但由于临床上发现胸闷、心悸为其主要症状，故可将其归纳为中医“心悸”、“胸痹”范畴。然而，其与传统中医“心悸”、“胸痹”存在一定的区别。李佩文发现，曲妥珠单抗所致心脏毒性主要为无形之“气”的病变，气为血之帅，气虚能影响血之化生而见血虚证表现，或气虚推动无力而见血瘀证表现，但曲妥珠单抗所致心脏毒性之根本仍在于“气”之病变 [<xref ref-type="bibr" rid="hanspub.43756-ref17">17</xref>]。徐志宏发现，乳腺癌术后患者以气虚为主，气虚则气血运行紊乱，血无气推动则致瘀血内阻，心脏作为血液循环的动力器官受累最为严重，所于，曲妥珠单抗所致心脏毒性的病因主要是气虚血瘀所致 [<xref ref-type="bibr" rid="hanspub.43756-ref18">18</xref>]。张洋则通过心与肝之间的“母子”关系，心肝在生理病理过程中紧密相关，提出心旺则肝亦旺；同时，心主血脉，肝藏学及主疏泄，血液之所以能够在脉道中运行，必须依赖于心气(情志)的推动。因此，曲妥珠单抗心脏毒性病机主要为心脉瘀阻，肝气郁结 [<xref ref-type="bibr" rid="hanspub.43756-ref19">19</xref>]。</p></sec><sec id="s9_3_2"><title>5.3.2. 辨证论治</title><p>对于曲妥珠单抗造成心脏毒性，李佩文 [<xref ref-type="bibr" rid="hanspub.43756-ref17">17</xref>] 注重补益心气，常用七福饮及归脾汤加减，注重黄芪、人参等益气药的应用。桑震池等 [<xref ref-type="bibr" rid="hanspub.43756-ref20">20</xref>] 发现黄芪总皂苷能能减轻心力衰竭大鼠的程度，证实了黄芪治疗心衰的疗效。从而验证了补益中气可防治曲妥珠单抗所致心脏毒性。朱慧发现 [<xref ref-type="bibr" rid="hanspub.43756-ref21">21</xref>] 人参可增强患者的心功能水平。另一项临床研究发现，心脉隆注射液可明显改善接受曲妥珠单抗治疗乳腺癌患者心功能不全的临床症状及心肌损伤程度，实验室检查发现其可降低血液黏度，抑制血清IL-6，TNF-α水平 [<xref ref-type="bibr" rid="hanspub.43756-ref18">18</xref>]。从而验证了补心益气法防治曲妥珠单抗所致心脏毒性。张洋 [<xref ref-type="bibr" rid="hanspub.43756-ref19">19</xref>] 等运用加味生脉饮预防曲妥珠单抗所致心脏毒性，发现预防性使用加味生脉饮的患者，治疗后LVEF明显高于未使用患者，故其能保护心肌，预防心脏毒性事件发生。此外，乔翠霞等 [<xref ref-type="bibr" rid="hanspub.43756-ref22">22</xref>] 运用生脉散加味治疗曲妥珠单抗所致心脏毒性，发现其可减轻心脏不良临床症状，提高患者耐受，改善生活质量，说明养阴益气法可有效减轻曲妥珠单抗所致心脏毒性。</p></sec></sec></sec><sec id="s10"><title>6. 小结</title><p>针对HER2阳性的乳腺癌患者，曲妥珠单抗联合化疗已成为一线治疗方案。心脏毒性是曲妥珠单抗使用过程中最主要及严重的不良反应。尽管其心脏毒性为II性心脏毒性，大部分患者结束靶向治疗后，心功能基本可恢复正常。但部分病人在靶向治疗过程中仍可出现明显LVEF降低，甚至发生心衰症状，只能因此终止治疗，影响患者预后。所以在用药前评估患者心功能，预防其心脏毒性的发生显得尤为重要。然而，由于其心脏毒性的机制尚未明确，目前西医大多以对症治疗为主，存在明显的局限性，暂无疗效确切、安全性高的预防手段。中医药在预防靶向治疗不良反应具有其独到的优势。中医以补气养血，益气养阴等为主要治疗原则，通过临床试验发现中医药可有效预防曲妥珠单抗所致心脏毒性，且安全性较好。是潜在的预防曲妥珠单抗心脏毒性的药物。但由于目前的临床试验仍存在样本量小、随访周期短等问题，临床推广仍存在一定的局限性。故后续研究应再次总结中医药的用药规律，开展更多高质量的临床试验，推动中医药事业的发展，进一步提高肿瘤患者的生活质量。</p></sec><sec id="s11"><title>文章引用</title><p>项莲莲,郝 炜. 曲妥珠单抗所致乳腺癌患者心脏毒性的中西医结合治疗进展Research Progress of the Treatment of Combined Traditional Chinese and Western Medicine on Cardiotoxicity of Breast Cancer Patients Caused by Trastuzumab[J]. 中医学, 2021, 10(04): 511-515. https://doi.org/10.12677/TCM.2021.104069</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43756-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">International Agency for Research on Cancer (2020) Latest Global Cancer Data: Cancer Burden Rises to 19.3 Million New Cases and 10.0 Million Cancer Deaths in 2020.  
https://www.iarc.fr/fr/news-events/latest-global-cancer-data-cancer-burden-rises-to-19-3-million-new-cases-and-10-0-million-cancer-deaths-in-2020/</mixed-citation></ref><ref id="hanspub.43756-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Milani, A., Montemurro, F., Gioeni, L., et al. (2010) Role of Trastuzumab in the Management of HER2-Positive Metastatic Breast Cancer. Breast Cancer, 2, 93-109. &lt;br&gt;https://doi.org/10.2147/BCTT.S6070</mixed-citation></ref><ref id="hanspub.43756-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Menna, P., Minotti, G. and Salvatorelli, E. (2019) Cardiotoxicity of Targeted Cancer Drugs: Concerns, “The Cart Before the Horse,” and Lessons from Trastuzumab. Current Cardiology Reports, 21, Article No. 33.  
&lt;br&gt;https://doi.org/10.1007/s11886-019-1121-0</mixed-citation></ref><ref id="hanspub.43756-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., et al. (2009) BCIRG 006: Phase III Trial Comparing AC-T with AC-TH and with TCH in the Adjuvant Treatment of HER2-Amplified Early Breast Cancer Patients: Third Planned Efficacy Analysis. Cancer Research, 69, 62. &lt;br&gt;https://doi.org/10.1158/0008-5472.SABCS-09-62</mixed-citation></ref><ref id="hanspub.43756-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Perez, E.A., Suman, V.J., Davidson, N.E., Sledge, G.W., Kaufman, P.A., Hudis, C.A., et al. (2008) Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with or without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 26, 1231-1238.  
&lt;br&gt;https://doi.org/10.1200/JCO.2007.13.5467</mixed-citation></ref><ref id="hanspub.43756-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rastogi, P., Jeong, J., Geyer, C.E., Costantino, J.P., Romond, E.H., Ewer, M.S., et al. (2007) Five Year Update of Cardiac Dysfunction on NSABPB-31, a Randomized Trial of Sequential Doxorubicin/Cyclophosphamide (AC)-Paclitaxel (T) vs.AC-T with Trastuzumab (H). Journal of Clinical Oncology, 25, LBA513.  
&lt;br&gt;https://doi.org/10.1200/jco.2007.25.18_suppl.lba513</mixed-citation></ref><ref id="hanspub.43756-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Suter, T.M., Procter, M., van Veldhuisen, D.J., Muscholl, M., Bergh, J., Carlomagno, C., et al. (2007) Trastuzumab- Associated Cardiac Adverse Effects in the Herceptin Adjuvant Trial. Journal of Clinical Oncology, 25, 3859-3865.  
&lt;br&gt;https://doi.org/10.1200/JCO.2006.09.1611</mixed-citation></ref><ref id="hanspub.43756-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Chen, T., Xu, T., Li, Y., Liang, C., Chen, J., Lu, Y., et al. (2011) Risk of Crdiac Dysfunction with Trastuzumab in Breast Cancer Patients: A Meta-Analysis. Cancer Treatment Reviews, 37, 312-320.  
&lt;br&gt;https://doi.org/10.1016/j.ctrv.2010.09.001</mixed-citation></ref><ref id="hanspub.43756-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李佳, 王阿曼, 吕海辰, 刘莹, 崔晓楠, 夏云龙, 等. 抗人类表皮生长因子受体-2药物疗效与“心”安全并重[J]. 中国医学前沿杂志(电子版), 2020(3): 19-26.</mixed-citation></ref><ref id="hanspub.43756-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Slamon, D.J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., et al. (2001) Use of Chemotherapy Plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer that Overexpresses HER2. New England Journal of Medicine, 344, 783-792. &lt;br&gt;https://doi.org/10.1056/NEJM200103153441101</mixed-citation></ref><ref id="hanspub.43756-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sawyer, D.B., Zuppinger, C., Miller, T.A., Eppenberger, H.M. and Suter, T.M. (2002) Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1beta and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity. Circulation, 105, 1551-1554.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.0000013839.41224.1C</mixed-citation></ref><ref id="hanspub.43756-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Crone, S.A., Zhao, Y.Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., et al. (2002) ErbB2 is Essential in the Prevention of Dilated Cardiomyopathy. Nature Medicine, 8, 459-465. &lt;br&gt;https://doi.org/10.1038/nm0502-459</mixed-citation></ref><ref id="hanspub.43756-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sengupta, P.P., Northfelt, D.W., Gentile, F., Zamorano, J.L. and Khandheria, B.K. (2008) Trastuzumab Induced Cardio Toxicity: Heart Failure at the Cross Roads. Mayo Clinic Proceedings, 83, 197-203.  
&lt;br&gt;https://doi.org/10.1016/S0025-6196(11)60840-9</mixed-citation></ref><ref id="hanspub.43756-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Lu, C.Y., Srasuebkul, P., Drew, A.K., Chen, K., Ward, R.L. and Pearson, S.-A. (2013) Trastuzumab Therapy in Australia: Which Patients with HER2 + Metastatic Breast Cancer Are Assessed for Cardiac Function? Breast, 22, 482-427.  
&lt;br&gt;https://doi.org/10.1016/j.breast.2013.04.011</mixed-citation></ref><ref id="hanspub.43756-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Swain, S.M., Ewer, M.S., Cortés, J., Amadori, D., Miles, D., Knott, A., et al. (2013) Cardiac Tolerability of Pertu- Zumab Plus Trastuzumab Plus Docetaxel in Patients with HER2-Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Double-Blind, Placebo-Controlled Phase III Study. Oncologist, 18, 257-264.  
&lt;br&gt;https://doi.org/10.1634/theoncologist.2012-0448</mixed-citation></ref><ref id="hanspub.43756-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Lipshultz, S.E., Rifai, N., Sallan, S.E., Lipsitz, S.R., Dalton, V., Sacks, D.B., et al. (1997) Predictive Value of Cardiac Troponin T in Pediatric Patients at Risk for Myocardial Injury. Circulation, 96, 2641-2648.  
&lt;br&gt;https://doi.org/10.1161/01.CIR.96.8.2641</mixed-citation></ref><ref id="hanspub.43756-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">周佳琳, 王照东方, 张静, 万冬桂. 李佩文教授辨治乳腺癌治疗相关心脏毒性经验[J]. 中国医药导报, 2020, 17(34): 146-149.</mixed-citation></ref><ref id="hanspub.43756-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">姚铁柱, 徐志宏, 马景涛, 张宁, 高威, 张守德, 等. 心脉隆注射液对曲妥珠单抗和蒽环类药物序贯化疗乳腺癌患者致心脏毒性气虚血瘀证的保护作用[J]. 中国实验方剂学杂志, 2016, 22(6): 154-158.</mixed-citation></ref><ref id="hanspub.43756-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">张洋, 刘晓菲, 朱晴, 王楠. 加味生脉饮对HER-2阳性乳腺癌赫赛汀所致心脏毒性防治作用研究[J]. 现代中西医结合杂志, 2020, 29(24): 2640-2643, 2683.</mixed-citation></ref><ref id="hanspub.43756-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">桑震池, 徐三彬, 钱俊峰, 许国军, 汪蔚青, 王大英, 等. 黄芪总皂苷对心力衰竭大鼠心功能及左室重构的影响[J]. 中西医结合心脑血管病杂志, 2017, 15(17): 2114-2116.</mixed-citation></ref><ref id="hanspub.43756-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">朱慧. 人参治疗慢性心力衰竭临床观察[J]. 光明中医, 2019, 34(8): 1208-1210.</mixed-citation></ref><ref id="hanspub.43756-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">乔翠霞, 张新峰, 程旭峰, 刘琦, 蔡小平. 生脉散加味与多西他赛联合曲妥珠单克隆抗体对有心脏高危因素的高龄胃癌患者的临床疗效[J]. 中国老年学杂志, 2019, 39(12): 2876-2878.</mixed-citation></ref></ref-list></back></article>